Detalles de la búsqueda
1.
Long-term intraocular pressure-lowering efficacy and safety of ripasudil-brimonidine fixed-dose combination for glaucoma and ocular hypertension: a multicentre, open-label, phase 3 study.
Graefes Arch Clin Exp Ophthalmol
; 2024 Mar 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38430227
2.
Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand.
J Infect Chemother
; 30(6): 536-543, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38154616
3.
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Cardiovasc Diabetol
; 20(1): 96, 2021 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33947390
4.
Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
Diabetes Obes Metab
; 23(7): 1660-1665, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33769665
5.
Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
Diabetes Obes Metab
; 22(2): 222-230, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31608549
6.
Association of increased hepatic insulin clearance and change in serum triglycerides or ß-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.
Diabetes Obes Metab
; 22(6): 947-956, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31984623
7.
Restricted mean survival time as a summary measure of time-to-event outcome.
Pharm Stat
; 19(4): 436-453, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32072769
8.
Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.
Diabetes Obes Metab
; 21(7): 1715-1724, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30945431
9.
Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study.
Diabetes Obes Metab
; 21(7): 1737-1744, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30830727
10.
Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination.
Int J Mol Sci
; 20(22)2019 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31698825
11.
Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment.
Int J Mol Sci
; 20(3)2019 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30736366
12.
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin.
Diabetes Obes Metab
; 20(4): 1061-1065, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29171930
13.
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
Diabetes Obes Metab
; 24(12): 2469-2473, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35979908
14.
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Cardiovasc Diabetol
; 13: 65, 2014 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-24678906
15.
Long-term Efficacy and Safety of K-924 Pitavastatin/Ezetimibe Fixed-dose Combination in Patients with Hypercholesterolemia: A Phase III, Multi-center, Open-label Trial.
J Atheroscler Thromb
; 31(3): 288-305, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37722882
16.
Reductions in liver enzymes are associated with anti-hyperglycaemic and anti-obesity effects of tofogliflozin in people with type 2 diabetes: Post-hoc analyses.
Endocrinol Diabetes Metab
; 7(1): e461, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37986236
17.
Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial.
J Atheroscler Thromb
; 2024 Apr 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38616112
18.
This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
Diabetes Obes Metab
; 20(8): 2041-2042, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29749099
19.
Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial.
J Atheroscler Thromb
; 30(11): 1580-1600, 2023 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36908150
20.
Ripasudil-Brimonidine Fixed-Dose Combination vs Ripasudil or Brimonidine: Two Phase 3 Randomized Clinical Trials.
Am J Ophthalmol
; 248: 35-44, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36410471